Tongxinluo Capsule (通心络胶囊) for Cardiac Syndrome X: A Systematic Review and Meta-Analysis

Hui-min Mao; Mi Liu; Hua Qu; Li-qiong Wang; Da-zhuo Shi

doi:10.1007/s11655-017-2762-8

Your Location：

Home >

Browse articles >

Tongxinluo Capsule (通心络胶囊) for Cardiac Syndrome X: A Systematic Review and Meta-Analysis

OriginalPaper | Updated：2021-08-27

- Tongxinluo Capsule (通心络胶囊) for Cardiac Syndrome X: A Systematic Review and Meta-Analysis
- Tongxinluo Capsule (通心络胶囊) for Cardiac Syndrome X: A Systematic Review and Meta-Analysis
- 中国结合医学杂志（英文版） 2018年24卷第4期页码：296-303
- Affiliations：
  
  1. Graduate School, Beijing University of Chinese Medicine,Beijing,China
  2. Cardiovascular Disease Center, Xiyuan Hospital, China Academy of Chinese Medical Sciences,Beijing,China
- Author bio：
- Funds：
- DOI：10.1007/s11655-017-2762-8
  中图分类号：
- 纸质出版日期：2018，
  
  网络出版日期：2017-8-17，
Scan for full text
Mao, Hm., Liu, M., Qu, H. et al. Tongxinluo Capsule (通心络胶囊) for Cardiac Syndrome X: A Systematic Review and Meta-Analysis., Chin. J. Integr. Med. 24, 296–303 (2018). https://doi.org/10.1007/s11655-017-2762-8

Hui-min Mao, Mi Liu, Hua Qu, et al. Tongxinluo Capsule (通心络胶囊) for Cardiac Syndrome X: A Systematic Review and Meta-Analysis[J]. Chinese Journal of Integrative Medicine, 2018,24(4):296-303.
Mao, Hm., Liu, M., Qu, H. et al. Tongxinluo Capsule (通心络胶囊) for Cardiac Syndrome X: A Systematic Review and Meta-Analysis., Chin. J. Integr. Med. 24, 296–303 (2018). https://doi.org/10.1007/s11655-017-2762-8 DOI：

Hui-min Mao, Mi Liu, Hua Qu, et al. Tongxinluo Capsule (通心络胶囊) for Cardiac Syndrome X: A Systematic Review and Meta-Analysis[J]. Chinese Journal of Integrative Medicine, 2018,24(4):296-303. DOI： 10.1007/s11655-017-2762-8.

摘要

To evaluate the efficacy and safety of Tongxinluo Capsule (通心络胶囊

TXL) for patients with cardiac syndrome X (CSX). Randomized controlled trials (RCTs) regarding TXL in the treatment of CSX were searched in Chinese Biomedicine Literature Database

China National Knowledge Infrastructure

Chinese Scientific Journal Database

Wanfang Database

PubMed

EMBASE

Cochrane Central Register of Controlled Trial

websites of the Chinese and International Clinical Trial Registry platform up to June 30

2015. The intervention was either TXL alone or TXL combined with conventional treatment

while the control intervention was conventional treatment with or without placebo. Data extraction

methodological quality assessment and data analyses were performed according to the Cochrane criteria. The primary outcome was a composite event of death

acute myocardial infarction (AMI)

angina requiring hospitalization

revascularization

and heart failure. The secondary outcome measures were angina symptom improvement

electrocardiograph (ECG) improvement

and serum endothelin-1 (ET-1) level. The adverse events were also recorded. RevMan 5.3 software was applied for data analyses. Twelve RCTs (696 patients) were included. Compared with conventional treatment

the addition of TXL to conventional treatment showed some benefits on relieving angina symptoms [risk ratio (RR): 1.46

95% confidence interval (CI) (1.25

1.71)

P<0.01]

and improving ECG [RR: 1.45

95% CI (1.21

1.74)

P<0.01]. The pooled result did not support a benefit of TXL on reducing the incidence of primary outcome [RR: 0.20

95% CI (0.02

1.61)

P=0.13]. In addition

TXL decreased serum ET-1 concentration of CSX patients [standardized mean number:–1.63

95% CI (–2.29

–0.96)

P<0.01]. No serious adverse events were reported. TXL documents potential benefits on attenuating angina symptoms

improving ECG and decreasing serum ET-1 level for CSX patients. However

more rigorous RCTs with high quality are needed to confirm its efficacy and safety.

Abstract

To evaluate the efficacy and safety of Tongxinluo Capsule (通心络胶囊

TXL) for patients with cardiac syndrome X (CSX). Randomized controlled trials (RCTs) regarding TXL in the treatment of CSX were searched in Chinese Biomedicine Literature Database

China National Knowledge Infrastructure

Chinese Scientific Journal Database

Wanfang Database

PubMed

EMBASE

Cochrane Central Register of Controlled Trial

websites of the Chinese and International Clinical Trial Registry platform up to June 30

2015. The intervention was either TXL alone or TXL combined with conventional treatment

while the control intervention was conventional treatment with or without placebo. Data extraction

methodological quality assessment and data analyses were performed according to the Cochrane criteria. The primary outcome was a composite event of death

acute myocardial infarction (AMI)

angina requiring hospitalization

revascularization

and heart failure. The secondary outcome measures were angina symptom improvement

electrocardiograph (ECG) improvement

the addition of TXL to conventional treatment showed some benefits on relieving angina symptoms [risk ratio (RR): 1.46

95% confidence interval (CI) (1.25

1.71)

P<0.01]

and improving ECG [RR: 1.45

95% CI (1.21

1.74)

P<0.01]. The pooled result did not support a benefit of TXL on reducing the incidence of primary outcome [RR: 0.20

95% CI (0.02

1.61)

P=0.13]. In addition

TXL decreased serum ET-1 concentration of CSX patients [standardized mean number:–1.63

95% CI (–2.29

–0.96)

P<0.01]. No serious adverse events were reported. TXL documents potential benefits on attenuating angina symptoms

improving ECG and decreasing serum ET-1 level for CSX patients. However

more rigorous RCTs with high quality are needed to confirm its efficacy and safety.

关键词

Tongxinluo capsulecardiac syndrome Xrandomized controlled trialsystematic reviewChinese Medicine

Keywords

Tongxinluo capsulecardiac syndrome Xrandomized controlled trialsystematic reviewChinese Medicine

references

Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095–2128.

Melikian N, De Bruyne B, Fearon WF, MacCarthy PA. The pathophysiology and clinical course of the normal coronary angina syndrome (cardiac syndrome X). Prog Cardiovasc Dis 2008;50:294–310.

Kaski JC, Rosano GMC, Collins P, Nihoyannopoulos P, Maseri A, Poole-Wilson PA. Cardiac syndrome X: clinical characteristics and left ventricular function. Long-term follow-up study. J Am Coll Cardiol 1995;25:807–814.

Gulati M, Cooper-DeHoff RM, Mc-Clure C, Johnson BD, Shaw LJ, Handberg EM, et al. Adverse cardiovascular outcomes in women with non-obstructive coronary artery disease: a report from the Women’s Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. Arch Intern Med 2009;169:843–850.

Crea F, Lanza GA. Angina pectoris and normal coronary arteries: cardiac syndrome X. Heart 2004;90:457–463.

Bi YF, Mao JY, Zhang ZP, Wang XL, Wang HH, Ge YB, et al. Research progress of traditional Chinese medicine for cardiac syndrome X. Shanghai J Tradit Chin Med (Chin) 2013;47:77–80.

Chen YJ, Huang XB, Chen WQ, Wang NQ, Chu YY. Clinical trials of Xuefu Zhuyu Capsule on cardiac syndrome X. Beijing J Tradit Chin Med (Chin) 2012;31:403–405.

Bi Y, Mao J, Wang X, Ge Y, Wang H, Zhang Z. Traditional Chinese medicine syndrome patterns and qi-regulating, chest-relaxing and blood-activating therapy on cardiac syndrome X. J Tradit Chin Med 2013;33:194–199.

Zhu HG, Chen H. The effect of Yixinshu Capsule on cardiac syndrome X and endothelial function. Chin J Integr Med Cardio Cerebrovasc Dis (Chin) 2014;12:680–682.

Wang JY, Xiao L, Chen J, Zhai JB, Mu W, Mao JY, et al. Potential effectiveness of traditional Chinese medicine for cardiac syndrome X (CSX): a systematic review and metaanalysis. BMC Complement Altern Med 2013;13:62.

Zhao JL, Yang YJ, You SJ, Jing ZC, Wu YJ, Yang WX, et al. Effect of Tongxinluo on endothelin-1 in the mini-swine model of acute myocardial infarction and reperfusion. Chin J Integr Med (Chin) 2005;25:902–906.

Duan L, Yang YJ, Zhang HT, Chen YT, Kang S, Zhao JL, et al. Protective effect of Tongxinluo on mini-swine model of acute myocardial infarction and reperfusion damaged by oxidative stress. Chin J Pathol (Chin) 2010;26:430–434.

Yang YJ, Zhang J, Wu YJ, Tang YD, Chen X, Yuan YM, et al. Protective effects of Tongxinluo, carvedilol and valsartan on microvascular endothelial function and integrity after late reperfused AMI in rabbits. Chin J Pathol (Chin) 2006;22:1366–1369.

Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011.

Agrawal S, Mehta PK, Bairey Merz CN. Cardiac syndrome X: update 2014. Cardiol Clin 2014;32:463–478.

Jia Y, Leung SW, Lee MY, Cui G, Huang X, Pan F. The efficacy of Guanxinning Injection in treating angina pectoris: systematic review and meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med 2013;2013:282707.

Liu H, Hu YC, Chen J. The effect of Tongxinluo Capsule on the vascular endothelial function in patients with cardiac syndrome X. Chin J Difficult Complicated Cases (Chin) 2003;2:218–219.

Lv XL, Zhao ZQ, Feng ZQ, Feng JY, Gu HM. The effect of Tongxinluo Capsule on the vascular endothelial function and inflammatory factors patients with cardiac syndrome X. J Clin Med Pract (Chin) 2014;18:135–136.

Li SY, Tang Q. The clinical observation on curative effect of Tongxinluo combined with Western medicines in 36 patients with cardiac syndrome X. Yunnan J Tradit Chin Med Mat Med (Chin) 2009;30:15–16.

Wang LB, Hu AX, Wang MS, Hong H, Yan DC. The clinical study on the therapeutic effect of Tongxinluo and diltiazem in patients with cardiac syndrome X. Chin J Med Guide (Chin) 2006;8:188–189.

Zhang Y, Zhang QM, Zheng Y. Clinical application of Tongxinluo Capsule in cardiac syndrome X. J Liaoning Univ Tradit Chin Med (Chin) 2008;10:82–83.

Lu H, Ma RR. Clinical observation on therapeutic effect of Tongxinluo Capsules on patients with cardiac syndrome X complicated by abnormality of coronary artery flow reserve. Chin J Difficult Complic Cases (Chin) 2007;6:655–657.

Zhou LP, Jiang SH, Xiong Q. Clinical observation on therapeutic effect of Tongxinluo in cardiac syndrome X. Chin J Integr Med Cardio Cerebrovasc Dis (Chin) 2012;10:868–869.

Liu ZY, Yin XG, Li ZL, Jin DQ, Chen ZQ. Clinical observation on therapeutic effect of Tongxinluo Capsules on patients with cardiac syndrome X. Chin J Integr Med Cardio Cerebrovasc Dis (Chin) 2013;11:1390–1391.

Niu TF, Liu PY, Geng Q, Qi HX, Wang JP, Yang XY, eds. Observation on Tongxinluo Capsule in treating patients with cardiac syndrome X. Basic and Clinical Research on collateral disease theory. Beijing: Military Medical Sciences Press; 2009:333–335.

Feng ZB, Li CM, Cheng RN, Yuan N. The clinical study of cardiac syndrome X treated with Tongxinluo Capsule. J Bethune Milit Med Coll (Chin) 2005;3:25–26.

Bi XP, Cai XJ, Wei F. Clinical observation on therapeutic effect of Tongxinluo in cardiac syndrome X. Heibei Med J (Chin) 2005;27:587.

Ma FJ, Xu JH. Clinical application study of Tongxinluo Capsules in cardiac syndrome X. Shanghai Pharm J (Chin) 2006;27:465–466.

FULL TEXT LINK

More>

浏览量

Downloads

CSCD

文章被引用时，请邮件提醒。

Submit

工具集

关联资源

Astragalus membranaceus Injection combined with conventional treatment for viral myocarditis: A systematic review of randomized controlled trials

Efficacy of externally applied Chinese herbal drugs in treating psoriasis: A systematic review

Efficacy and safety of Flos Abelmoschus manihot (Malvaceae) on type 2 diabetic nephropathy: A systematic review

Shenqi Fuzheng Injection (参芪扶正注射液) for advanced gastric cancer: A systematic review of randomized controlled trials

Toward Evidence-Based Chinese Medicine: Status Quo, Opportunities and Challenges